TScan Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 154
- Market Cap
- $292.9M
- Website
- http://www.tscan.com
- Introduction
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Clinical Trials
8
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Long Term Follow-up Study of TScan TCR-T Products
- Conditions
- AMLALLMDS
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06976736
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Mount Sinai, New York, New York, United States
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease
- Conditions
- Autoimmune DiseasesUlcerative ColitisMultiple SclerosisSclerodermaAnkylosing SpondylitisCeliac DiseaseNon-radiographic Axial Spondyloarthritis (nr-axSpA)Crohn's DiseaseBirdshot Chorioretinitis
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06587828
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology, PLLC, Phoenix, Arizona, United States
🇺🇸Inland Empire Gastroenterology, Murrieta, California, United States
🇺🇸Knowledge Research Center, Orange, California, United States
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Conditions
- HPV - Anogenital Human Papilloma Virus InfectionHPV-Related Squamous Cell CarcinomaHPV-Related Endocervical AdenocarcinomaHPV-Related Anal Squamous Cell CarcinomaHPV-Related Penile Squamous Cell CarcinomaHPV-Related Vulvar Squamous Cell CarcinomaHPV Positive Rectal Squamous Cell CarcinomaHPV-Related Cervical CarcinomaHPV-Associated Vaginal AdenocarcinomaMelanoma
- Interventions
- Biological: TSC-204-A0201 + TSC-204-C0702Biological: TSC-204-A0201 + TSC-200-A0201Biological: TSC-204-C0702 + TSC-200-A0201Biological: TSC-204-A0201 + TSC-203-A0201Biological: TSC-204-C0702 + TSC-203-A0201Biological: TSC-204-A0201 + TSC-204-A0101Biological: TSC-204-A0201 + TSC-201-B0702Biological: TSC-204-C0702 + TSC-204-A0101Biological: TSC-204-C0702 + TSC-201-B0702Biological: TSC-200-A0201 + TSC-203-A0201Biological: TSC-200-A0201 + TSC-204-A0101Biological: TSC-200-A0201 + TSC-201-B0702Biological: TSC-203-A0201 + TSC-204-A0101Biological: TSC-203-A0201 + TSC-201-B0702Biological: TSC-204-A0201 + TSC-202-A0201Biological: TSC-204-C0702 + TSC-202-A0201Biological: TSC-200-A0201 + TSC-202-A0201Biological: TSC-203-A0201 + TSC-202-A0201Biological: TSC-204-A0101 + TSC-202-A0201Biological: TSC-201-B0702 + TSC-202-A0201
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 840
- Registration Number
- NCT05973487
- Locations
- 🇺🇸
HonorHealth Research and Innovation Institute, Scottsdale, Arizona, United States
🇺🇸University of California San Diego, San Diego, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
- Conditions
- Head and Neck CancerCervical CancerNon Small Cell Lung CancerHPV16 Related CancersSarcomaUveal MelanomaNUT Carcinoma
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 1150
- Registration Number
- NCT05812027
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
- Conditions
- AMLMyelodysplastic SyndromesALL, Adult
- Interventions
- Other: ControlDrug: SOC + TSC-100Drug: SOC + TSC-101
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05473910
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸City of Hope, Duarte, California, United States
- Prev
- 1
- 2
- Next